Stephanie Molden, MD
Obstetrics & Gynecology · Newtown, PANPI 1538193156
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (38.1%), education and travel and lodging — rather than concentrated in one kind of arrangement. Coloplast accounts for 83.1% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $46,192 and has fallen 64.1% since, to $16,591 in 2025. Among obstetrics & gynecology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 250 payments — averaging $368.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$77K
- Caldera Medical, Inc$6K
- Contura, Inc.$3K
- Femselect Inc.$2K
- Boston Scientific$2K
- Axonics, Inc.$469
- plus $2K from 21 others
Across 83 payments — averaging $1166.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coloplast$52K
- Axonics, Inc.$43K
- Femselect Inc.$2K
What the payments were for
- Consulting fees$35,11638%
- Speaking & faculty fees$9001%
- Travel & lodging$15,39917%
- Food & beverage$8,1669%
- Education$31,83235%
- Gifts$5891%
- Entertainment$1820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 130 | $76,580 |
| Caldera Medical, Inc | 30 | $5,985 |
| Contura, Inc. | 5 | $3,235 |
| Femselect Inc. | 1 | $2,000 |
| Boston Scientific | 10 | $1,579 |
| Axonics, Inc. | 11 | $469 |
| Surgalign Spine Technologies, Inc. | 1 | $450 |
| Sumitomo Pharma America, Inc. | 13 | $326 |
| BD | 1 | $255 |
| Medtronic(2 entities) | 6 | $229 |
| Escala Medical Inc. | 2 | $181 |
| Intuitive Surgical | 1 | $180 |
| Astellas Pharma US Inc | 7 | $142 |
| Urovant Sciences Inc | 7 | $128 |
| Pfizer | 6 | $82 |
| Merz North America, Inc. | 1 | $71 |
| Therapeuticsmd, Inc. | 5 | $67 |
| Urocure LLC | 2 | $36 |
| Mission Pharmacal Company | 2 | $36 |
| Revance Therapeutics, Inc. | 1 | $29 |
| AMAG Pharmaceuticals, Inc. | 2 | $26 |
| Provepharm Inc. | 1 | $22 |
| Abbott | 1 | $21 |
| AbbVie | 1 | $16 |
| Galderma Laboratories, L.p. | 1 | $16 |
| Millicent US Inc | 1 | $13 |
| Ferring Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTIS$73,430
- Desara$4,925
- Bulkamid$3,191
- NEUGUIDE$2,000
- GENERAL FEMALE SUI$900
- Coloplast AXIS$450
- GENERAL - THERAPIES$400
- Axonics$259
- Da Vinci Surgical System$180
- Saffron$159
- INTERSTIM$144
- GENERAL PELVIC ORGAN PROLAPSE$100
How this compares
$92,184 in reported general payments places this provider in the 95th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 75 | $56,908 |
| MyrbetriqMirabegron | 77 | $45,160 |
| Estradiol | 100 | $6,296 |
| PremarinEstrogens, Conjugated | 12 | $5,531 |
| Methenamine Hippurate | 50 | $4,040 |
| Trospium Chloride ErTrospium Chloride | 15 | $2,511 |
| Solifenacin Succinate | 19 | $596 |
| Clobetasol Propionate | 13 | $497 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 22 | $363 |
| Ciprofloxacin Hcl | 20 | $58 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $326 | $56,90875 claims |
| Astellas Pharma US IncMyrbetriq | $142 | $45,16077 claims |
| PfizerPremarin | $82 | $5,53112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.
Other obstetrics & gynecology in Newtown
- Stephen KlaskoPhiladelphia$2.2M
- Stephanie SoberPhiladelphia$1.8M
- Barry JacobsonGlen Mills$302K
- Timothy GrubeFrackville$260K
- Russell StankiewiczLewisburg$202K
- Jamille Nagtalon-RamosPhiladelphia$183K
- Timothy DeimlingMechanicsburg$182K
- Gerald HarkinsMechanicsburg$140K
- Kirthik ParthasarathyWest Reading$103K
- Catherine ChappellPittsburgh$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.